Insmed

Historical price data

Insmed is a patient-centric, global biopharma leader with a mission to deliver transformative therapies for serious and rare diseases. The company has achieved significant commercial and clinical milestones, including regulatory approvals and advanced late-stage pipelines, underpinned by a culture consistently recognized as a top employer. Its strategy hinges on deep patient collaboration, a synergistic technology platform spanning drug delivery and small molecules, and a disciplined focus on high-need pulmonary and rare disease markets.

A multi-modality platform synergistically combining advanced drug delivery systems (e.g., liposomal inhalation) with novel small molecule discovery to create targeted therapies for serious diseases.

Insmed competes in specialized segments of the respiratory and rare disease markets. It holds a first-in-class position with Arikayce in MAC lung disease but faces competition from off-label regimens. In bronchiectasis and pulmonary hypertension, it will contend with both established standards of care and novel agents in development, requiring clear differentiation on efficacy, safety, and convenience.